Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
YONDELIS (Specialised Therapeutics Pharma Pty Ltd)
Product name
YONDELIS
Date registered
Evaluation commenced
Decision date
Approval time
193 (255 working days)
Active ingredients
trabectedin
Registration type
NCE/NBE
Indication
YONDELIS (powder for injection) is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.